VERNER B. CALLOMON, M.D.; JOHN UNGAR JR., M.D.
The value of the conventional antipneumococcus sera, both unconcentrated and concentrated, has been shown to lie for the greater part in their content of type-specific protective antibodies. Unfortunately, their field of usefulness has been restricted chiefly to Type I infections, although there is some evidence of activity in Type II and in Types VII and VIII infections.1 In Type III and most Group IV infections evidence of any curative value is lacking. For some years immunologic observations have been accumulating which have led to the preparation of an antipneumococcus serum containing additional immune factors.
In 1911 Forssman2 observed that the
CALLOMON VB, UNGAR J. TREATMENT OF PNEUMONIA WITH SERUM CONTAINING TYPE-SPECIFIC, HETEROPHILE, AND NEUTRALIZING ANTIBODIES(TREATMENT OF PNEUMONIA WITH SERUM CONTAINING TYPE-SPECIFIC, HETEROPHILE, AND NEUTRALIZING ANTIBODIES*). Ann Intern Med. 1936;9:1664–1676. doi: 10.7326/0003-4819-9-12-1664
Download citation file:
Published: Ann Intern Med. 1936;9(12):1664-1676.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use